BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Anastrozole readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Anastrozole\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07163481-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Anastrozole: Phase 1 readout est. (NCT07163481)
DESCRIPTION:Anastrozole\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocri
 ne Therapy in Patients With HR-positive\, HER2-negative Metastatic Breast 
 Cancer Progressed on CDK4/6 Inhibitors\nEstimated primary completion: Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anastrozol
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 163481
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05780567-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Anastrozole: Phase 3 readout est. (NCT05780567)
DESCRIPTION:Anastrozole\, phase 3.\nStudy: Clinical Study on Adjuvant Thera
 py of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combin
 ed With Endocrine Therapy in Patients With Breast Cancer\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/anastrozole#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05780567
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04886531-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Anastrozole: Phase 2 readout est. (NCT04886531)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzum
 ab in ER-Positive\, HER-2 Positive Breast Cancers\nEstimated primary compl
 etion: 22 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/anastrozole#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04886531
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04553770-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Anastrozole: Phase 2 readout est. (NCT04553770)
DESCRIPTION:Anastrozole\, phase 2.\nStudy: Trastuzumab Deruxtecan Alone or 
 in Combination With Anastrozole for the Treatment of Early Stage HER2 Low\
 , Hormone Receptor Positive Breast Cancer\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anas
 trozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04553770
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07212712-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Anastrozole: Phase na readout est. (NCT07212712)
DESCRIPTION:Anastrozole\, phase na.\nStudy: The Role of Estrogen and Testos
 terone in Determining Brain Blood Flow and Metabolic Regulation in Humans\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07212712
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04906395-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Anastrozole: Phase 3 readout est. (NCT04906395)
DESCRIPTION:Anastrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Bre
 ast Cancer\nEstimated primary completion: 30 January 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04906395
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02476786-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Anastrozole: Phase 2 readout est. (NCT02476786)
DESCRIPTION:Anastrozole\, phase 2.\nStudy: Endocrine Treatment Alone for El
 derly Patients With Estrogen Receptor Positive Operable Breast Cancer and 
 Low Recurrence Score\nEstimated primary completion: 31 January 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/anastrozole#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT02476786
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06179303-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Anastrozole: Phase 2 readout est. (NCT06179303)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Functional Imaging in Prediction of Response to Abemaciclib for Advan
 ced Hormone Receptor-Positive\, HER2-Negative Breast Cancer\nEstimated pri
 mary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/anastrozole#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06179303
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501704-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Anastrozole: Phase 2 readout est. (NCT05501704)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: ETHAN - ET for Male BC\nEstimated primary completion: 1 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/anastrozole#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05501704
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01953588-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Anastrozole: Phase 3 readout est. (NCT01953588)
DESCRIPTION:Anastrozole\, phase 3.\nStudy: Fulvestrant and/or Anastrozole i
 n Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergo
 ing Surgery\nEstimated primary completion: 1 April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT01953588
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05586802-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Anastrozole: Phase 3 readout est. (NCT05586802)
DESCRIPTION:Anastrozole\, phase 3.\nStudy: Sex Steroids Balance for Metabol
 ic and Reproductive Health in Klinefelter Syndrome\nEstimated primary comp
 letion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/anastrozole#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05586802
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04469764-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Anastrozole: Phase 2 readout est. (NCT04469764)
DESCRIPTION:Anastrozole\, phase 2.\nStudy: Abemaciclib for the Treatment of
  Recurrent Ovarian or Endometrial Cancer\nEstimated primary completion: 1 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anastrozol
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 469764
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03304080-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Anastrozole: Phase 1/2 readout est. (NCT03304080)
DESCRIPTION:Anastrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Anastrozole\, Palbociclib\, Trastuzumab and Pertuzumab in HR-positi
 ve\, HER2-positive Metastatic Breast\nEstimated primary completion: 31 Jul
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/anastrozole#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03304
 080
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05837455-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Anastrozole: Phase 2 readout est. (NCT05837455)
DESCRIPTION:Anastrozole\, phase 2.\nStudy: NeoTAILOR: ABiomarker-directed A
 pproach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-pos
 itive\, HER2-negative Breast Cancer\nEstimated primary completion: 30 Nove
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anastrozol
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 837455
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935317-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Anastrozole: Phase 2 readout est. (NCT07935317)
DESCRIPTION:Anastrozole\, phase 2.\nStudy: A Study of Tersolisib (LY4064809
 ) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutat
 ed Early Breast Cancer\nEstimated primary completion: December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/anastrozole#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07935317
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07568574-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Anastrozole: Phase na readout est. (NCT07568574)
DESCRIPTION:Anastrozole\, phase na.\nStudy: Impact of Medically Supervised 
 Performance-Enhancing Substances (PES) on Elite Athletes\nEstimated primar
 y completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/anastrozole#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07568574
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891093-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Anastrozole: Phase 3 readout est. (NCT05891093)
DESCRIPTION:Anastrozole\, phase 3.\nStudy: Efficacy and Safety of Fluzopari
 b Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Earl
 y Breast Cancer (BCTOP-L-A01)\nEstimated primary completion: 31 May 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/anastrozole#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05891093
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02942355-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Anastrozole: Phase 2 readout est. (NCT02942355)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Brea
 st Cancer\nEstimated primary completion: 30 June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02942355
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604272-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Anastrozole: Phase 1 readout est. (NCT07604272)
DESCRIPTION:Anastrozole\, phase 1.\nStudy: Reversing InGuinal Hernia Trial:
  The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males\nEsti
 mated primary completion: July 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/anastrozole#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07604272
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05467891-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Anastrozole: Phase 2 readout est. (NCT05467891)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregi
 onal Recurrent\, Resected Hormone Receptor Positive HER2 Negative Breast C
 ancer\nEstimated primary completion: 15 August 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05467891
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06086704-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Anastrozole: Phase 2 readout est. (NCT06086704)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Study of 18F-FFNP Breast PET/MRI\nEstimated primary completion: 31 Au
 gust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anastrozol
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 086704
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06075953-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Anastrozole: Phase 2 readout est. (NCT06075953)
DESCRIPTION:Anastrozole\, phase 2.\nStudy: DCIS: RECAST Trial Ductal Carcin
 oma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability 
 as Treatment\nEstimated primary completion: November 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06075953
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05524584-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Anastrozole: Phase 2 readout est. (NCT05524584)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Anastrazole\, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breas
 t Cancer\nEstimated primary completion: 31 December 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05524584
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061717-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Anastrozole: Phase 3 readout est. (NCT07061717)
DESCRIPTION:Anastrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Comparing Endocrine Therapy Combined With High-Dose Palbociclib and H
 ydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palboci
 clib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cance
 r\nEstimated primary completion: 1 July 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07061717
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391774-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Anastrozole: Phase 3 readout est. (NCT07391774)
DESCRIPTION:Anastrozole\, phase 3.\nStudy: Testing Whether Hormone Therapy 
 With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therap
 y With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer W
 ith Low Recurrence Risk\, The RxFINE-Low Trial\nEstimated primary completi
 on: 31 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ana
 strozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07391774
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492616-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Anastrozole: Phase 3 readout est. (NCT06492616)
DESCRIPTION:Anastrozole\, phase 3.\nStudy: A Study of Elacestrant Versus St
 andard Endocrine Therapy in Women and Men With ER+\,HER2-\, Early Breast C
 ancer With High Risk of Recurrence\nEstimated primary completion: August 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/anastrozole#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06492616
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380751-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Anastrozole: Phase 3 readout est. (NCT06380751)
DESCRIPTION:Anastrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy\, Com
 pared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in
  HR-Positive\, HER2-Negative (IHC 0\, 1+\, 2+/ ISH Non-amplified)\, BRCA1\
 , BRCA2\, or PALB2m Advanced Breast Cancer\nEstimated primary completion: 
 18 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ana
 strozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06380751
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05645536-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Anastrozole: Phase 3 readout est. (NCT05645536)
DESCRIPTION:Anastrozole\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Safety Extension Study for Subjects With HR+\, HER2- Breast Cancer fo
 r Subjects Who Have Completed the OVELIA Study\nEstimated primary completi
 on: March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anast
 rozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05645536
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05161195-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Anastrozole: Phase 4 readout est. (NCT05161195)
DESCRIPTION:Anastrozole\, phase 4\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Roll-over Study to Allow Continued Access to Ribociclib\nEstimated pr
 imary completion: 28 June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/anastrozole#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05161195
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Anastrozole: Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Anastrozole\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in 
 Combination With Other Antineoplastic Agents in Participants With Advanced
  Solid Tumors\nEstimated primary completion: July 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716046-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Anastrozole: Phase 2 readout est. (NCT07716046)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/
 HER2+ Advanced Breast Cancer\nEstimated primary completion: 31 August 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/anastrozole#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07716046
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953882-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Anastrozole: Phase 2 readout est. (NCT06953882)
DESCRIPTION:Anastrozole\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: Impact of Omitting Chemo Based on Patient's Selection for ER-Positive
 \, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy\nEsti
 mated primary completion: September 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/anastrozole#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06953882
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581834-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Anastrozole: Phase 2 readout est. (NCT07581834)
DESCRIPTION:Anastrozole\, phase 2.\nStudy: Efficacy and Safety of Dalpicicl
 ib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Ca
 ncer: a Multicenter\, Prospective Clinical Study\nEstimated primary comple
 tion: 31 December 2031. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/anastrozole#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07581834
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06223698-8888@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20320502
DTEND;VALUE=DATE:20320503
SUMMARY:Anastrozole: Phase 3 readout est. (NCT06223698)
DESCRIPTION:Anastrozole\, phase 3.\nStudy: Optimizing Extended Adjuvant End
 ocrine Therapy in Patients With Breast Cancer\nEstimated primary completio
 n: 2 May 2032. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/anastr
 ozole#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06223698
URL:https://assetmemo.bio/drug/anastrozole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
